viewCytoDyn Inc.

CytoDyn seeks UK approval for its flagship drug leronlimab for HIV and coronavirus

The company said a BLA-type submission is planned this month in the UK for a 350 mg weekly dose of leronlimab as part of a HIV combo therapy

CytoDyn Inc. -
CytoDyn has completed its Phase 2 clinical trial for COVID-19, a randomized clinical trial for mild-to-moderate patients in the US and is currently evaluating the data

CytoDyn Inc (OTCQB:CYDY), which is developing leronlimab (PRO 140) to battle multiple diseases, said Friday that it will submit requests for pre-submission meetings in the UK for the drug as an HIV treatment in combination with highly active antiretroviral therapy (HAART), for highly treatment-experienced HIV patients, as a 350 mg self-injectable dose.

In addition, the Vancouver, Washington-based company said it will seek emergency approval of leronlimab for coronavirus (COVID-19) patients with mild-to-moderate symptoms.

CytoDyn said it will share its topline report from the Phase 2 trial, along with the Clinical Study Report (CSR). The company will also prepare requests for pre-submission meetings in European Union member countries.

READ: CytoDyn files to uplist to tech-heavy Nasdaq stock exchange

The company's submission to the UK government’s Medicines and Healthcare Products Regulatory Agency (MHRA) will initiate the process to seek approval for leronlimab as a combination therapy for treatment-experienced HIV patients using a 350 mg weekly dose. The company’s Phase 3 trial for leronlimab as a combination therapy for highly treatment-experienced HIV patients met its primary endpoint (p = 0.0032) for the trial based on a 350 mg dosage, self-injectable, once-a-week.

In a statement, CytoDyn CEO Nader Pourhassan said: “We have been working with MHRA and have provided requested information and we are hopeful that we can quickly and efficiently move forward with the process of potentially bringing leronlimab to global communities in need.” 

He added: “We will also pursue cancer indications in all these countries, as well as other potential indications for leronlimab.”                                                                                                     

The Phase 2 trial to evaluate the effectiveness and safety of leronlimab in patients with mild-to-moderate symptoms caused by COVID-19 infection was completed in July 2020. Patients were randomized to receive weekly doses of 700 mg leronlimab, or placebo administered as injections. The patients receiving leronlimab experienced 64% fewer serious adverse events during the trial than patients receiving just a placebo.

CytoDyn’s ongoing Phase 3 (CD12) trial of leronlimab in patients with severe to critical COVID-19 was reviewed by an independent Data Safety Monitoring Committee (DSMC), which reported finding "no cause" to modify the study. The Phase 3 study currently has 173 enrolled patients and the company will conduct a full interim analysis once 195 patients are enrolled.

The US Food and Drug Administration (FDA) has granted Fast Track designation to CytoDyn as a combination therapy with HAART for HIV-infected patients, and for metastatic triple-negative breast cancer, a rare variety which doesn’t respond to some treatments. 

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Quick facts: CytoDyn Inc.

Price: 2.67 USD

Market: OTCQB
Market Cap: $1.52 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...


CytoDyn achieves 75% enrollment for its severe-to-critical coronavirus...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotechnology company has achieved the enrollment of 293 patients with severe-to-critical coronavirus symptoms, meeting the criteria for a second interim analysis by the Data Safety Monitoring Committee (DSMC). Pourhassan says...

1 week, 1 day ago

3 min read